Cancers, Vol. 10, Pages 215: Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia

Cancers, Vol. 10, Pages 215: Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia

Cancers doi: 10.3390/cancers10070215

Authors: Francesco Buccisano Richard Dillon Sylvie D. Freeman Adriano Venditti

Minimal (or measurable) residual (MRD) disease provides a biomarker of response quality for which there is robust validation in the context of modern intensive treatment for younger patients with Acute Myeloid Leukemia (AML). Nevertheless, it remains a relatively unexplored area in older patients with AML. The lack of progress in this field can be attributed to two main reasons. First, physicians have a general reluctance to submitting older adults to intensive chemotherapy due to their frailty and to the unfavourable biological disease profile predicting a poor outcome following conventional chemotherapy. Second, with the increasing use of low-intensity therapies (i.e., hypomethylating agents) differing from conventional drugs in mechanism of action and dynamics of response, there has been concomitant skepticism that these schedules can produce deep hematological responses. Furthermore, age-dependent differences in disease biology also contribute to uncertainty on the prognostic/predictive impact on older adults with certain genetic abnormalities including younger patients validated for MRD monitoring. This review examines the evidence for the role of MRD as a prognosticator in older AML, together with the possible pitfalls of MRD evaluation in older age.

https://ift.tt/2N1dIAf